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ABSTRACT
Background: 40% of people with dementia have disturbed sleep but there are currently no known effective
treatments. Studies of sleep hygiene and light therapy have not been powered to indicate feasibility and
acceptability and have shown 40–50% retention. We tested the feasibility and acceptability of a six-session
manualized evidence-based non-pharmacological therapy; Dementia RElAted Manual for Sleep; STrAtegies
for RelaTives (DREAMS-START) for sleep disturbance in people with dementia.
Methods: We conducted a parallel, two-armed, single-blind randomized trial and randomized 2:1 to
intervention: Treatment as Usual. Eligible participants had dementia and sleep disturbances (scoring ≥4 on
one Sleep Disorders Inventory item) and a family carer and were recruited from two London memory services
and Join Dementia Research. Participants wore an actiwatch for two weeks pre-randomization. Trained,
clinically supervised psychology graduates delivered DREAMS-START to carers randomized to intervention;
covering Understanding sleep and dementia; Making a plan (incorporating actiwatch information, light
exposure using a light box); Daytime activity and routine; Difficult night-time behaviors; Taking care of
your own (carer’s) sleep; and What works? Strategies for the future. Carers kept their manual, light box,
and relaxation recordings post-intervention. Outcome assessment was masked to allocation. The co-primary
outcomes were feasibility (≥50% eligible people consenting to the study) and acceptability (≥75% of
intervention group attending ≥4 intervention sessions).
Results: In total, 63out of 95 (66%; 95% CI: 56–76%) eligible referrals consented between 04/08/2016 and
24/03/2017; 62 (65%; 95% CI: 55–75%) were randomized, and 37 out of 42 (88%; 95% CI: 75–96%)
adhered to the intervention.
Conclusions: DREAM-START for sleep disorders in dementia is feasible and acceptable.
Key words: sleep disorders, carers, cognitive behavioral therapy (CBT), randomized controlled trial (RCT), physical activity
Introduction
Currently, 47 million people live with dementia
worldwide, with numbers expected to nearly triple
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by 2050 because of increasing longevity (Prince
et al., 2015). Sleep disturbances are common
in dementia, for example, occurring in around
40% of people with Alzheimer’s disease (AD)
(Moran et al., 2005; Dauvilliers, 2007; Zhao,
2016). Causes of sleep disturbance are varied
and include pain relating to comorbid disorders,
disorientation to time of day, or neuropsychiatric
symptoms, including anxiety and depression. In
addition, dementia may impair the sleep–wake
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cycle through degeneration of the suprachiasmatic
nucleus, disrupting the normal circadian rhythm
(Ju et al., 2014). Sleep disruption reduces everyday
function and quality of life (Kyle et al., 2010).
It also increases family carer burden, predicts
depressive symptoms, and leads to care home
admissions, thus increasing individual, societal, and
economic costs associated with dementia (McCrae
et al., 2016; Livingston et al., 2017).
There are, however, currently no known
effective treatments for sleep problems in dementia,
although there have been trials of drugs, including
mirtazapine and melatonin which have been
ineffective (McCleery et al., 2014; Livingston et al.,
2017). Other studies incorporating sleep hygiene
and light therapy have been too small for definitive
results (McCurry et al., 2009; Forbes et al., 2014;
Kinnunen et al., 2017). Health teams use a mixture
of sleep hygiene measures and psychotropic med-
ication, extrapolated from other conditions, that
give limited benefit, and medications may have side
effects. Bright light therapy to strengthen circadian
rhythmicity has some effect on sleep disturbances
in the general population (McCurry and Ancoli-
Israel, 2003). Cognitive behavioral techniques for
sleep management have been effective in older
adults without dementia and in family carers of
people with dementia (Montgomery and Dennis,
2003; Sivertsen and Nordhus, 2007).
The objective of this study is to test the feasibility
and acceptability of Dementia RElAted Manual
for Sleep; STrAtegies for RelaTives (DREAMS-
START), a multicomponent manualized interven-
tion built on the above available evidence, to
manage clinically significant sleep disturbance in
people with dementia living in their own homes.
Methods
Study design and participants
This is a two-armed randomized controlled trial,
recruiting from three UK sites; Camden and
Islington NHS Foundation Trust, Barnet, Enfield
and Haringey Mental Health NHS Trust, and
Join Dementia Research (JDR), where people
register their interest in participating in dementia
research. London – Queen Square Research Ethics
Committee (Reference: 16/LO/0670) approved
the study. We obtained written consent from
all participating family carers and patients with
the mental capacity to give informed consent to
participation in the trial prior to their enrollment. If
the person with dementia did not have capacity to
give consent, we required a consultee’s declaration.
The trial steering committee provided overall
supervision of the trial with an independent
chairperson leading it. The full protocol is in the
Appendix (see online supplementary material).
Eligible patients from the trusts lived in their
own home, had a clinical diagnosis of dementia and
a sleep disorders inventory (SDI) item score ≥4
(Tractenberg et al., 2003), judged as problematic
by the person with dementia or their family,
and had a primary family carer who provided
support at least weekly. People with dementia,
who had a primary sleep disorder diagnosis, such
as sleep apnoea, were excluded. Patients and
carers were assessed at home after consent and
at follow-up three months later. The baseline
measures included socio-demographic details and
dementia severity through the Clinical Dementia
Rating (CDR), a reliable and valid instrument for
classifying clinically diagnosed dementia (Hughes
et al., 1982; Morris, 1997) as very mild (0.5), mild
(1), moderate (2) or severe (3). After enrollment,
we asked patients to wear wrist-worn actiwatches
(MotionWatch 8) CamNtech Ltd. 24 h a day
for two weeks before randomization and again at
follow-up.
Randomization and masking
An independent statistician produced computer-
generated randomization lists stratified by site and
based on random permuted blocks of sizes three
and six to allow 2:1 allocation to intervention:
Treatment as Usual (TAU) groups. Therapists
worked in two separate teams of two therapists each
and assessed outcomes for participants, to whom
the other team had delivered the intervention,
masked to group allocation. A third non-therapist
researcher assessing outcomes was masked to all
allocations. Due to the intervention’s nature it was
not possible to mask the trial participants. When
arranging follow-up, participants were reminded
not to disclose their allocation group to the
assessor, and to remove from view anything related
to DREAMS-START.
Procedures
Those allocated to the intervention received the six-
session DREAMS-START manual. We developed
DREAMS-START for the study in an iterative co-
production process, involving dementia and sleep
experts and Public and Patient Input (PPI) (PR,
GL, SK, CE, CC with PPI led by RH and JP).
We incorporated prior evidence, some existing
materials and used the START manual structure
(Livingston et al., 2013; Livingston et al., 2014).
This iterative coproduction is reported in detail
elsewhere (Kinnunen et al., 2017). DREAMS-
START comprised cognitive-behavioral compon-
ents, including psychoeducation, light therapy,
establishing a new sleep–wake schedule (based on
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Six sessions comprising:  
1. Understanding sleep and demena: Psychoeducaon on the importance of sleep, sleep 
process, the impact of demena upon sleep, lifestyle and bedroom environment factors 
that could aﬀect sleep, the impact that sleep problems can have upon the person with 
demena and their relave. 
2. Making a plan: Plan for the person with demena to increase natural and arﬁcial light; 
standardise meal mes; changes to bed and rise mes; reduce dayme naps (plan based 
upon the individual’s acgraphy data and sleep diary). Establishing adapve smulus 
control: pre-bed seling roune and management of wakeful episodes. The carers were 
given a ‘light box’ (Lumie Arabica SAD Light, Lumie, Cambridge, UK) to keep and it was le 
on during the sessions to help people become habituated to the bright light
(10,000 lux at 25cm). We provided a me switch if carers wanted it and 
recommended it was le on for 30 minutes at the same me every morning. 
3. Dayme acvity and roune: Promong de-arousal at night (e.g. relaxaon, bedroom 
comfort, no caﬀeine or alcohol intake before bed, no acvies in bedroom) and 
behavioural acvaon during the day to maintain alertness, reduce dayme naps. Building 
pleasant acvies and exercise/physical acvity into the day, including a seated exercise 
video for less physically able individuals. Every individual made an exercise and acvity 
plan. 
4. Diﬃcult night-me behaviours: Troubleshoong around pung the individual plan into 
acon and idenfying potenal soluons to any barriers. Describing and invesgang 
diﬃcult night me behaviours speciﬁc to the individual with demena.  
5. Taking care of your own (carer’s) sleep: Using the informaon collected on diﬃcult night-
me behaviours to create strategies for managing these diﬃcules. Carer managing their 
own sleep, including ways to challenge unhelpful thoughts and feelings and make me for 
themselves. 
6. What works? Strategies for the future: This focuses upon what carers have found useful. 
From this an individualised sleep acon plan is ﬁnalised, which includes strategies for both 
the person with demena and the carer. 
Each session, aer the ﬁrst one, followed a similar structure. They began with a recap of last 
week’s session, and a discussion about what the carer had achieved since then. The new topic was 
then introduced, and the carer and therapist generated relevant, individually-tailored plans that 
the carer could implement in the coming week. At the end of the session, the therapist talked the 
carer through a new relaxaon exercise.  At the end carers kept their manual, light box and 
relaxaon recordings post-intervenon. 
Figure 1. Structure of DREAMS-START manual.
review of actiwatch data), behavioral activation,
relaxation, and coping skills for families (see,
Figure 1 for details of DREAMS-START). Trained
and clinically supervised psychology graduates
delivered it to carers at home, unless the carer
requested to have sessions elsewhere. Each session
lasted about 1 h, and took place approximately
weekly, at a time convenient to the carer. The
sessions were delivered to the family carer, unless
a paid carer was with the person around the clock,
and therefore would be most likely to implement
strategies. We encouraged the carers to have the
sessions by themselves, so they could talk without
potentially distressing the person with dementia.
However, if people with dementia wanted to
participate they were included in the sessions.
Our clinical psychologist, PR, met each team of
therapists for 1.5 h of group supervision fortnightly.
Additionally, she was available for individual
supervision, requested by the psychology graduates
on an ad hoc basis, or occasionally initiated by
the investigators. If the therapists had any urgent
concerns they approached PR, CC, or GL (e.g. if
risk issues arose). The group supervision format
was to ensure good case management, clinical skills
development and safe practice, and to maximize
peer support.
PR devised a fidelity checklist comprising the
most important components of each session.
Therapist’s audio-recorded one session selected
at random by the trial manager per participant.
The other therapist in the same team then rated
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the recording for “keeping the session to time,”
“keeping the carer focused on the manual,”
“keeping the carer engaged in the session,” and
“managing the concerns of the carer.” Scores
ranged from 1 “not at all” to 5 “very focused.”
All participants received TAU. This was
expected to vary between trusts and patients,
but be in line with the NICE dementia guidelines
(NICE/SCIE, 2006), consisting of assessment,
diagnosis, symptomatic interventions, risk
assessment and management, and information.
These included medication; cognitive stimulation
therapy; neuropsychiatric symptoms treatment;
driving advice; medical identification (ID)
bracelets; capacity assessment and advice
regarding power of attorney; referral to dementia
advisors/navigators for signposting and to social
services for personal care, tableware, day center
and financial advice, and carer support (START in
some trusts). We also gathered details of services
the JDR volunteers received.
After the follow-up data had been collected,
the control group participants received a summary
of the baseline actiwatch data, with advice on
improving sleep.
Outcomes
Trained research team member, masked to group
assignment, assessed patients for outcomes. The
primary outcomes were feasibility of recruitment
and treatment adherence. These were assessed by
(1) the proportion of eligible carers consented;
(2) the proportion randomized after baseline
assessment; and (3) acceptability of DREAMS-
START by adherence. The secondary outcomes
were referral rates; follow-up rates at three months;
all psychotropic medication prescription (to define
rescue medication’s role); reported side effects: co-
morbid physical illnesses and patient falls; and feas-
ibility and acceptability of interview schedules and
actigraphy assessed through instrument completion
rates.
We collected sleep measures (interview and
actigraphy) before randomization and three months
after. Actigraphy estimates sleep and wakefulness
from movement and time, and has been used
previously in a small trial to improve sleep for
people with dementia (McCurry et al., 2005).
We asked carers to define each participant’s sleep
analysis window, either by recording the person
with dementia’s bed and rise times in a sleep
diary, or by pressing the actiwatch’s “event marker”
button. The SDI (Tractenberg et al., 2003) is a
valid and reliable seven-item measure of a person
with dementia’s sleep disturbance. Scores ≥4 on
individual items equate to clinically significant sleep
disturbance and study eligibility. The SDI total
(sum of items) score ranges from 0 to 84. The
alternative SDI mean global score is calculated
as the mean frequency × mean severity (range
0–12). Daytime sleepiness was measured using
the validated eight-item Epworth Sleepiness Scale
(ESS) (Johns, 1994; Spira et al., 2012). Possible
scores range 0–24, with >10 indicating excessive
sleepiness. We measured overall neuropsychiatric
symptoms using the neuropsychiatric inventory
(NPI) (Cummings et al., 1994) at baseline and
three months. This validated instrument has 12
neuropsychiatric symptoms domains (scored 0–
12). The possible highest score is 144. Higher
scores mean increasing severity. Quality of life was
measured using the DEMQOL-Proxy (Smith et al.,
2007), a 31-item interviewer-administered valid
and reliable instrument for dementia, which can be
used with the Client Service Receipt Inventory to
calculate cost-effectiveness (Mulhern et al., 2012).
We collected data on the family carers, including
sleep, commonly disrupted by person with de-
mentia’s sleep–wake patterns, using the validated,
reliable Pittsburgh Sleep Quality Index (PSQI)
(Buysse et al., 1989), and the Sleep Condition
Indicator (SCI) (Espie et al., 2014), an eight-
item scale, characterizing sleep both dimensionally
and against insomnia disorder criteria. Mood was
measured using the validated, reliable Hospital
Anxiety and Depression Scale (HADS) (Bjelland
et al., 2002; Snaith, 2003), and subjective burden
using the validated Zarit Burden Interview (ZBI)
(Zarit et al., 1980). Carer’s quality of life was
measured on the Health Status Questionnaire-12
(HSQ-12), a 12-item scale (Pettit et al., 2001;
Barry et al., 2007).
Sample size
We estimated that with 40 intervention participants
(larger to allow a more precise estimate of pro-
portion adhering to intervention) and 20 controls,
we would achieve the following 95% confidence
interval (CI) for our expected adherence and
participation estimates:
1. Proportion of participants adhering to intervention
– expected value 75%, 95% CI: 59–87%
2. Proportion of appropriate referrals consenting to
the trial – expected value 50%, 95% CI: 41–59%
This sample size was also judged as sufficient
for estimating the standard deviation as required
for the sample size calculation in the main trial.
We envisaged in our protocol that it would
be actigraphy but that we would be open to
change this from information in the trial, and we
would also have information to calculate sample
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size using the scales in the trial. Our estimated
recruitment referral rate was approximately six
potential participants per week. Two out of
these were expected to be suitable and agree
to participate. Our expected follow-up rate was
approximately 80%.
The 95% CI for expected adherence and
participation estimates would provide acceptable
ranges to inform continuation to the main trial. We
specified our “stop–go” measures would be related
to the proportion adhering, with ≥70% meaning
proceed to a main trial.
Analysis
For all eligible patients and carers, we summarized
recruitment site and sex of the person with
dementia, and carer sex and relationship to
the person with dementia comparing those who
consented with those who did not. We calculated
with 95% CI: proportion of screened patients
who were eligible for the trial, proportion of
eligible referrals consenting to the trial, proportion
of participants in each randomized group who
dropped out or were lost to follow-up, proportion of
participants in the intervention group who adhered
to DREAMS-START (attended a ≥4/6 sessions),
median number of sessions attended by those in
the intervention group. The frequency (%) of
participants in each randomized group who had
taken psychotropic drugs and melatonin during
the three months prior to the baseline and follow-
up was calculated. Frequency (%) of co-morbid
physical illnesses and patient falls was summarized
by randomized group at baseline and three months.
We summarized socio-demographic character-
istics and baseline and follow-up actigraphy meas-
ures and other scores using means (with standard
deviations), medians (with interquartile ranges,
IQR), counts and proportions, as appropriate. The
actigraphy data were analyzed using MotionWare
Software 1.1.25. We defined each sleep period,
using the bed and rise times in the sleep diary
or by event markers. We used the carer’s verbal
report when neither was available. When unsure,
two researchers edited a sleep period and reached
a consensus. We removed from non-parametric
circadian rhythm analysis (NPCRA) periods of
missing data >3 h and excluded sleep data based
on fewer than seven nights. For exploratory sleep
analyses, we defined “core night-time” as midnight
to 6 am.
The number of participants with available data
was summarized for each outcome.
Follow-up carer and patient questionnaire scores
were compared between randomized groups using
regression models to provide estimates of the
effect of DREAMS-START with 95% CI (e.g.
difference in means), adjusted for baseline score
and site. Ordinary least squares regression was
used except for SDI scores where assumptions of
the model were violated and quantile (median)
regression methods were used. Formal analysis
for sleep measures at 3 months was focused on
sleep efficiency (time asleep\time in bed), relative
amplitude, activity count for most restful hours and
activity count for most active hours (predefined in
analysis plan). Regression models were adjusted for
baseline score and site. Ordinary least squares were
used where appropriate, otherwise estimates were
obtained from quantile (median) regression.
Results
Participant recruitment and flow
The flow of participants through the trial is
described using a CONSORT diagram (Figure 2).
We were referred 123 people through memory
clinics from 04/08/2016 to 03/04/2017. We stopped
recruiting when we were confident that we would
have sufficient randomized participants. The study
was open to JDR recruitment from 22/11/2016
to 24/03/2017. We found 140 potential people in
JDR, who lived in the area and had registered
as having dementia and a family supporter, and
contacted 27 using their preferred means (25 by
email; 2 by phone) from 05/12/2016 to 21/03/2017.
We followed up email by phone calls; 19 did not
respond, 3 were ineligible (2 had no sleep problems;
1 was moving out of London), for one person we
could only speak to the person with dementia and
were unable to determine eligibility. 95/120 (79%;
95% CI 71–86%) people assessed were eligible.
Comparison of those who consented with
those who did not
Table 1 compares consenters and non-consenters
demographic details and shows the study had good
external validity. The care recipients who did not
consent were, however, more often male.
Table 2 compares demographic and diagnostic
details of the randomized groups. Overall there was
a good demographic mix with recruitment from a
range of ethnicities, age groups and relationship
between the person with dementia and their carer.
There was a range of diagnoses with most people
having AD or a mixed dementia. Most primary
carers (45; 73%) lived with the person with
dementia, 4 lived with another family member,
so 49/62 (79%) lived with family members, 6
(10%) had paid carers living with them, and 7
(11%) had family carers but lived alone. The carers
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Referrals from memory clinics (n=123) 
Approached from JDR (n=27) 
 Assessed for eligibility (n=120) 
 Not assessed for eligibility (n=30) 
[died (n=1), unable to talk to carer (n=5), 
uncontactable (n=24)] 
Excluded (n= 58) 
 Not meeting inclusion criteria (n=25) 
 Declined to participate (n=32) 
Other reasons (n=1) 
[Withdrew before randomisation (n=1)] 
Lost to follow-up (n=4) 
 Withdrawn (n=3) 
 Died (n=1)  
Discontinued intervention <4 sessions (n=3) 
Lack of time, did not find it helpful (n=1) 
 Person with dementia declined (n=2) 
Allocated to intervention (n=42) 
 Received allocated intervention (n=40) 
[Attended all 6 sessions (n=36), attended ≥4 
sessions (n=37)] 
 Did not receive intervention (n=2) 
[Lack of time (n=1), person with dementia 
declined (n=1)]
Lost to follow-up (n=1) 
 Withdrawn (n=1) 
Allocated to treatment as usual (n=20) 
 Received allocated intervention (n=20) 
Allocaon 
Follow-Up 
Randomised 
(n=62) 
Enrolment 
Figure 2. (Colour online) CONSORT flow diagram: Summary of recruitment and follow-up.
in the intervention group included more women,
were younger and less likely to be co-residents or
spouses. The people with dementia in the interven-
tion group were more likely to be women and more
had a diagnosis of AD than in the TAU group.
Primary outcomes
63 (66%; 95% CI 56–76%) of eligible referrals
consented (61 from memory clinics and 2 from
JDR) and 62/95 (65%; 95% CI 55–75%) of whom
were randomized. In 8 cases, we consented two
carers who were involved in the intervention (3
people had two family carers; 5 had one family, and
1 paid carer).
Intervention adherence and delivery
We randomized 42 people to DREAMS-START, 2
dropped out before commencement. The median
number of sessions attended was 6; 37 (88%, 95%
CI 75–96%) attended ≥4 and 3 (7%) attended
1–3 sessions. Intervention delivery duration was a
median of 49.5 days (IQR = 43–64.5). On average,
each session took 69 min. The intervention was
delivered by four trained and supervised psychology
graduates, two women and two men, who were
ethnically white British (3) and Asian British (1).
Their ages ranged from 23–33 years. The therapists
visited all but two participants in their homes; one
was seen for one session at UCL and another for all
sessions at a Memory Service.
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Table 1. Characteristics of those eligible but did not consent vs. those who consented and were randomized
person with not consented randomized p-value
dementia (N = 33) (N = 62) (χ2 test)
............................................................................................................................................................................................................................................................................................................................
Site Camden and Islington 24 (73%) 40 (65%)
Barnet, Enfield & 7 (21%) 20 (32%)
Haringey
Join Dementia Research 2 (6%) 2 (3%) p = 0.46
Sex Male 20 (61%) 19 (31%)
Female 13 (39%) 43 (69%) p = 0.008
carer not consented randomized
(N = 33) (N = 62)
Carer sex Male 11 (33%) 18 (29%)
Female 22 (67%) 44 (71%) p = 0.67
Relationship to person Spouse 9 (28%) 19 (31%)
with dementia
Child/child in law 22 (69%) 41 (66%) (spouse vs. other)
Other 1 (3%) 2 (3%) p = 0.80
Sessions were delivered to 21 carers without
the person with dementia present; comprising
18 interventions with the family carer alone, 2
interventions with paid carers (1 with one paid
carer and 1 with three paid carers), and 1 delivered
to a family carer and a paid carer together.
In 5/21 of these interventions, the person with
dementia was present in the same room, but did
not participate as they did not want to or could not
(due to auditory or cognitive impairment).
For 13 dyads, both the person with dementia
and their carer attended every session. In others,
the person with dementia participated in some
sessions: 12 interventions were delivered with the
person with dementia and their family carer and
1 intervention with the person with dementia,
their family carer and paid carer. One person with
dementia participated in all sessions, but their
family carer only in three.
Fidelity was rated for 34/40 (85%) participants
who started DREAMS-START; three refused
recording, two stopped DREAMS-START before
the planned recording, and one recording was
partial and unscorable. Managing the carer’s
concerns and keeping the carer engaged in the
session median score was 5/5 (IQRs: 4–5 and 4.25–
5, respectively), keeping the carer focused on the
manual and keeping to time was rated 4/5 (IQRs:
4–5 and 3.25–5).
Secondary outcomes
Referral rates
Four potential participants were referred by the
memory clinics weekly.
Follow-up rates
57/62 (92%) of those randomized were followed up
at 3 months. Loss to follow-up in the intervention
group was 4/42 (9.5%; exact 95% CI 3–23%)
and in the TAU group 1/20 (5%; exact 95%
CI 0.1–25%): two withdrew consent, two were
uncontactable, and one person with dementia died
(Figure 2).
All psychotropic medication prescription
At baseline and 3 month follow-up, 19 (45%) and
16 (43%) of the intervention group received at
least 1 prescription of psychotropic medication or
melatonin, respectively. The corresponding TAU
numbers were 9 (45%) and 8 (44%).
Comorbid illness and side-effects
Table 3 shows comorbid illnesses at baseline and
comorbid illness and possible side effects at three
months. There is no clear difference between the
groups.
Potential outcomes for the main trial
Table 4 summarizes scores of patient and carer
questionnaires at baseline and 3 months and
indicates numbers with available data for each.
At baseline, the NPI, PSQI, SCI, and HSQ were
completed for 61/62 (98.4%). Other measures
were 100% completed. Summary scores are similar
between the two groups, although carers in the
intervention group had consistently better scores
than TAU.
Over 90% of those randomized completed the
SDI, HADS, ZBI, SCI, and the HSQ at 3 months.
Over 85% completed the other questionnaires.
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Table 2. Baseline demographic data and diagnostic characteristics by randomized group
person with dementia intervention (N = 42) TAU (N = 20)
............................................................................................................................................................................................................................................................................................................................
Site Camden and Islington 27 (64%) 13 (65%)
Barnet, Enfield & Haringey 14 (33%) 6 (30%)
Join Dementia Research 1 (2%) 1 (5%)
Sex Male 9 (21%) 10 (50%)
Female 33 (79%) 10 (50%)
Age (years) Mean (SD) 80.4 (9.0) 79.6 (7.0)
Lived with/alone Family carer 28 (67%) 17 (85%)
Another family member 3 (7%) 1 (5%)
Paid carer 5 (12%) 1 (5%)
Alone 6 (14%) 1 (5%)
Diagnosis Alzheimer’s disease 22 (52%) 7 (35%)
Dementia with Lewy bodies 2 (5%) 3 (15%)
Mixed 8 (19%) 4 (20%)
Vascular dementia 8 (19%) 6 (30%)
Alcohol-related dementia 1 (2%) 0 (0%)
Unspecified 1 (2%) 0 (0%)
Age left education (years) Mean (SD) 15.7 (3.7) (N = 40) 16.4 (4.9) (N = 19)
Marital status Single 1 (2%) 1 (5%)
Married 17 (40%) 11 (55%)
Divorced 1 (2%) 0 (0%)
Widowed 23 (55%) 8 (40%)
Ethnic group White 27 (64%) 13 (65%)
Asian 3 (7%) 3 (15%)
Black 7 (17%) 2 (10%)
Other 5 (12%) 2 (10%)
CDR global Very mild 5 (12%) 3 (15%)
Mild 16 (38%) 6 (30%)
Moderate 18 (43%) 9 (45%)
Severe 3 (7%) 2 (10%)
carer intervention (N = 42) tau (N = 20)
Carer sex Male 10 (24%) 8 (40%)
Female 32 (76%) 12 (60%)
Carer age (years) Mean (SD) 56.15 (13.54) 59.09 (12.22)
Family carer co-resident Yes 28 (67%) 17 (85%)
Relationship to person with dementia Spouse 10 (24%) 9 (45%)
Child/child in law 30 (72%) 11 (55%)
Grandchild 1 (2%) 0
Friend 1 (2%) 0
Carer ethnicity White 29 (69%) 14 (70%)
Asian 3 (7%) 3 (15%)
Black 7 (17%) 1 (5%)
Other 3 (7%) 2 (10%)
Notes: The numbers are frequency (%) unless otherwise stated.
Summary data indicate generally better scores for
the intervention group for both patient and carer
measures. After adjusting for site and baseline
score, statistically significant improvements due to
intervention are evident for ESS, DEMQOL-Proxy,
and ZBI.
Table 5 shows baseline sleep data for those
wearing the actiwatches for ≥7 nights with
complete data (i.e. not including 24-h periods
with >3 h of missing data). Only 1/62 participants
with dementia randomized did not wear the watch
for ≥7 nights at baseline. The sleep diary or event
markers were used by 50/62 (81%) of randomized
participants to record the person with dementia’s
bed and rise times. Of the remaining 12, 8 (13%)
gave a verbal report of sleep pattern, while 4 (6%)
did not. Table 6 shows the follow-up sleep data.
Overall, there was follow-up data for 49/62 (79%)
randomized; 6/57 (10.5%) randomized and still in
the study refused to wear the watch again; 49/51
(96%) of those who did wear it had actigraphy data
for at least seven days. Carers of 42 (82%) of these
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Table 3. Summary of comorbid illness and side
effects by randomized group
intervention tau
........................................................................................................................................................
Baseline (N = 42) (N = 20)
Falls 17 (40%) 7 (35%)
Gastro 21 (50%) 9 (45%)
Neurological 19 (45%) 10 (50%)
Infections 14 (34%) 6 (30%)
Other 6 (14%) 2 (11%)
3 Months (N = 38) (N = 18)
Falls 16 (42%) 7 (39%)
Gastro 16 (42%) 4 (22%)
Neurological 15 (39%) 10 (56%)
Infections 18 (47%) 5 (28%)
Other 9 (24%) 9 (50%)
Notes: The numbers are frequency (%).
participants provided their relative’s bed and rise
times via the sleep diary or event markers. Of the
remaining 11, eight (16%) provided a verbal report
of their relative’s sleep pattern.
Discussion
This is the first non-pharmacological randomized
controlled trial for sleep problems in dementia
powered to find if the intervention was feasible
and acceptable. It met predetermined criteria to
proceed to a full trial. It was not powered for
efficacy and our efficacy results are indicative rather
than definitive. One measure of acceptability is the
adherence rates to the intervention, and a good
adherence rate is a matter of judgment, with clinical
trials of medication for people being treated for
chronic illnesses reporting rates of 43–78% (Os-
terberg and Blaschke, 2005). Our predetermined
level in this trial was a relatively high rate of
75%, which was exceeded. In addition, most of
those in the intervention group found it acceptable
in that they attended all sessions once they had
started.
This trial shows that it is possible to deliver a
complex manual-based intervention and measures
fidelity. These results indicate that it should
be possible to deliver the intervention reliably
in future. High fidelity was achieved measured
through predetermined fidelity check lists and
sessions were recorded and fidelity measured.
While each possible intervention was mentioned,
therapists and carers were explicitly told that if
something was not applicable then to mention it
as a principle but not go into detail or make it a
goal e.g. if someone was wheelchair bound not to
suggest they went out walking daily. Recruitment
rates and consent were high from those referred by
health professionals but we found that a research
register may be a less fruitful source of recruitment
possibly because people may register and then their
circumstances may change. Generally, 80% follow-
up or above is regarded as satisfactory, and we
achieved 92%. JDR did not meet our criteria for
recruitment.
At follow-up, less than 80% of people random-
ized had enough actigraphy data to analyze and
only 68% had sleep diary/event marker data. We
originally envisaged that actigraphy data would
be the full trial primary outcome, but we are
unlikely to have the level of data required for
this. Families thought the person they looked after
was sleeping better, but the actigraphy results
did not support this. Actigraphy infers “sleep”
from lack of activity during the sleep window.
Movement is in contrast directly measured. There
is little actigraphy validation data in people with
dementia, who may frequently stay still while
awake or may sleep during the day. It has been
validated against polysomnography (PSG), with
good accuracy at detecting sleep (96.5%), but
not at detecting wakefulness (32.9% accuracy)
throughout the age range. Validity worsened with
increasing age (Marino et al., 2013). In older
women without dementia (mean age 69 years)
actigraphy results were unacceptable for those
with low sleep efficiency (Taibi et al., 2013). The
algorithms are also not designed to detect daytime
sleepiness. This suggests that it is important that
better methods of measuring sleep in people with
dementia are measured and it is possible that
WiFi enabled headbands may work better. There
was, however, indications from actigraphy, that
intervention participants were more active during
the day and less active at night. These accord with
the validated instruments results.
We achieved high completion rates of the
questionnaire measures using carers as informants.
The scores on the instruments are useful to
inform the design of a full trial. The SDI was
completed at follow-up by 90% of those initially
recruited to the trial. This appeared to be the most
practical way to measure sleep for future studies
in this area. Summary data for the carer-reported
instruments indicated generally better scores for
the intervention group, including a significant
improvement in both quality of life of people
with dementia and daytime sleepiness despite the
small numbers and that the comparator group,
TAU were receiving secondary care interventions.
There was also no increase in numbers using
rescue medication or indication of important harms
in terms of side-effects in either group. The
consistency in the direction of all the results
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Table 4. Completion rates and scores of baseline and three month follow-up patient and carer validated
interview measures by randomized group
person with dementia baseline
intervention
(N = 42) tau (N = 20)
............................................................................................................................................................................................................................................................................................................................
SDI global score Median (IQR) 2.57 (1.35 to
3.67)
2.98 (1.85 to
3.96)
SDI total score Median (IQR) 26.5 (19 to 36) 32.5 (20.5 to 40)
ESS total score Mean (SD) 9.95 (6.02) 8.85 (6.31)
NPI total score Mean (SD) 42.02 (23.17) 46.90 (23.48)
(N = 41)
DEMQOL-Proxy Mean (SD) 87.57 (10.73) 88.51 (10.14)
carer baseline intervention
(N = 42)
tau (N = 20)
PSQI global score Mean (SD) 9.22 (4.08)
(N = 41)
10.40 (4.52)
SCI total score Mean (SD) 15.32 (8.22)
(N = 41)
13.50 (5.92)
HADS scores Anxiety: Mean
(SD)
8.17 (4.66) 9.30 (3.80)
Depression: Mean
(SD)
5.24 (4.33) 7.65 (4.60)
Total: Mean (SD) 13.40 (8.35) 17.05 (7.80)
ZBI score Mean (SD) 37.69 (18.39) 38.30 (19.27)
HSQ scores Physical health:
Mean (SD)
67.89 (32.79)
(N = 41)
52.50 (39.47)
Mental health:
Mean (SD)
60.95 (23.17) 52.33 (24.02)
person with dementia three month intervention
(N = 42)
tau (N = 20) adjusted tr effect
(i-tau) (95% ci)b
SDI global score Median (IQR) 0.92 (0.49 to
2.94)
2.43 (0.82 to
3.88)
−0.30 (−1.42 to 0.82)a
SDI total score 0
to 84
Median (IQR) 16 (9 to 29)
(N = 38)
30 (14 to 37)
(N = 18)
−7 (−17.53 to 3.53)a
ESS total score Mean (SD) 7.17 (5.87)
(N = 36)
9.00 (7.55)
(N = 18)
−2.86 (−5.54 to −0.17)
(N = 54)
DEMQOL-Proxy Mean (SD) 93.52 (10.12)
(N = 37)
87.07 (10.22)
(N = 18)
7.08 (2.25 to 11.91)
(N = 55)
NPI total score Mean (SD) 38.69 (23.57)
(N = 36)
44.72 (23.22)
(N = 18)
−1.99 (−11.66 to 7.68)
(N = 54)
carer three months intervention
(N = 42)
tau (N = 20) adjusted tr effect
(i-tau) (95% ci)b
PSQI global score Mean (SD) 9.37 (4.16)
(N = 38)
9.5 (4.49)
(N = 18)
1.03 (−1.05 to 3.11)
(N = 55)
SCI total score Mean (SD) 15.45 (7.45)
(N = 38)
14.53 (8.54)
(N = 19)
−0.41 (−3.75 to 2.93)
(N = 56)
HADS scores Anxiety Mean (SD) 8.76 (5.57) 9.05 (4.22) 1.13 (−0.31 to 2.56)
Depression Mean (SD) 5.71 (4.43) 8.79 (4.88) −1.05 (−3.01 to 0.91)
Total Mean (SD) 14.47 (9.20)
(N = 38)
17.84 (8.43)
(N = 19)
0.51 (−2.39 to 3.42)
(N = 57)
ZBI score Mean (SD) 36.5 (17.07)
(N = 38)
42.16 (16.45)
(N = 19)
−5.32 (−9.83 to −0.82)
(N = 57)
HSQ scores Physical
health
Mean (SD) 68.42 (32.60)
(N = 38)
54.39 (35.94)
(N = 19)
3.12 (−12.27 to 18.52)
(N = 57)
Mental
health
Mean (SD) 55.96 (26.19)
(N = 38)
48.07 (21.15)
(N = 19)
1.25 (−9.52 to 12.02)
(N = 57)
IQR = interquartile range; SD = standard deviation.
aQuantile (median) regression.
bEstimates are from models adjusted for baseline score and site. Regression is OLS unless otherwise indicated.
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Table 5. Baseline sleep and non-parametric circadian rhythm analysis measures by randomized group
intervention tau
sleep measures N = 41 N = 20
............................................................................................................................................................................................................................................................................................................................
Sleep efficiency (%)a Median (IQR) 76.90 (66.60 to 83.00) 80.68 (70.75 to 86.30)
Average sleep time (min) Median (IQR) 448.00 (376 to 503) 442.00 (388 to 568.50)
Average wake time (min) Median (IQR) 111 (77 to 152) 114 (58.5 to 147.5)
Average time of lights
out/bedtime (24 h)b
Median (IQR) 22:26 (22:07 to 23:08) 22:25 (21:37 to 23:25)
Average time of falling
asleep (24 h)b
Median (IQR) 22:43 (22:07 to 23:40) 22:45 (22:04 to 00:16)
Average time of waking up
(24 h)
Median (IQR) 08:10 (07:41 to 8:54) 08:20 (07:48 to 8:46)
Average time of getting up
(24 h)
Median (IQR) 08:14 (07:52 to 09:00) 08:23 (07:56 to 08:56)
Average time in bed (h) Mean (SD) 9.91 (1.35) 10.01 (1.80)
non-parametric circadian rhythm analysis meas-
ures
N = 42 N = 20
Relative amplitude Median (IQR) 0.71 (0.48 to 0.82) 0.78 (0.56 to 0.90)
Inter-daily stability Mean (SD) 0.38 (0.16) 0.43 (0.17)
Intra-daily variability Mean (SD) 1.11 (0.40) 1.03 (0.32)
L5 – average activity count
for five most restful hours
Median (IQR) 1381 (572 to 1919) 761 (358.5 to 1616)
Start hour of five most
restful hours (24 h)b
Median (IQR) 01:00 (00:00 to 03:00) 01:00 (00:00 to 02:00)
Median (IQR) 8155 (5127 to 12281) 8212.0 (3730.5 to
14545.5)
Start hour of ten most
active hours (24 h)
Median (IQR) 10:00 (8:00 to 12:00) 8:30 (8:00 to 11:00)
core night-time sleep measures N = 41 N = 20
Sleep efficiency (%)a Median (IQR) 76.4 (68.1 to 83.9) 81.3 (67.15 to 91.05)
Average sleep time (min) Median (IQR) 278 (245 to 303) (N = 39) 300 (246 to 331) (N = 19)
Average wake time (min) Median (IQR) 57 (47 to 75) (N = 39) 52 (26 to 76) (N = 19)
Notes: Sleep and core night-time measures are for those ≥7 nights of data available. Non-parametric circadian rhythm analysis (NPCRA)
data are those calculated with all 24-h periods with >3 h of missing data excluded.
IQR = interquartile range; SD = standard deviation.
aTime asleep\time in bed.
bTo calculate summaries, times have been ordered from midday one day until midday the next day.
suggests they may be real. It is important if our
intervention reduces daytime sleepiness, in contrast
to sedative medication, which sometimes increases
it. Similarly, quality of life is an important outcome
for someone with dementia, as an intervention
may improve one domain while reducing overall
quality of life. Correspondingly, the carers in the
intervention group indicated reductions in stress
and burden.
The PPI judged the important outcomes were
that the person with dementia was less restless
at night, more awake during the day, disturbed
the carer less and seemed happier (which the
SDI measures). In these circumstances, they
were unsure that actigraphy added information,
or was accurate. Although some carers were
disappointed with actigraphy feedback, the carers
and therapists found the actigraphy information
from baseline helped to delineate the rest-activity
pattern and help make a plan. We would continue
to incorporate this in the intervention manual in a
full trial.
Future trials and interventions require a degree
of flexibility about who receives the intervention.
We had expected we would deliver an intervention
mainly to family carers alone, but the intervention
was delivered to family carers, paid carers, and
sometimes to both. Frequently, the person with
dementia was also included, and in one case half
of the sessions were delivered to a person with
dementia alone. Delivering the intervention with
the person with dementia present, although not
always problematic, presented challenges for the
therapists; for example, when the person with
dementia denied having any difficulties with sleep.
One person with dementia had some sessions alone,
but could not retain the information and make use
of the sessions. In any future trial, we suggest that
people with dementia could jointly participating in
the intervention sessions, with additional training
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Table 6. Three-month sleep and non-parametric circadian rhythm analysis measures by randomized group
sleep measures N = 32
intervention
N = 17
tau
N = 49
adjusted tr
effect ( i -tau)
(95% ci) a
............................................................................................................................................................................................................................................................................................................................
Sleep efficiency (%)b Median (IQR) 76.05 (65.0 to 81.9) 78.6 (72.1 to 82.3) 0.39 (−4.89 to
5.68)c
Average sleep time
(min)
Median (IQR) 418.5 (383.5 to 506) 475 (396 to 534)
Average wake time
(min)
Median (IQR) 112.5 (94.5 to
157.5)
105 (88 to 133)
Average time of lights
out/bedtime (24h)d
Median (IQR) 22:15 (21:36 to
22:50)
22:03 (21:21 to
23:28)
Average time of
falling asleep
(24 h)d
Median (IQR) 22:49 (21:59 to
23:23)
22:22 (21:39 to
23:55)
Average time of
waking up (24 h)
Median (IQR) 08:04 (07:16 to
08:38)
08:09 (07:38 to
08:41)
Average time of
getting up (24 h)
Median (IQR) 08:06 (07:20 to
08:44)
08:17 (07:48 to
08:43)
Average time in bed
(h)
Mean (SD) 9.89 (1.83) 10.05 (1.83)
non-parametric circadian rhythm ana-
lysis measures
N = 34 N = 17 N = 51
Relative amplitude Median (IQR) 0.71 (0.49 to 0.87) 0.76 (0.51 to 0.90) −0.02 (−0.10 to
0.06)c
Inter-daily stability Mean (SD) 0.38 (0.18) 0.47 (0.19)
Intra-daily variability Mean (SD) 1.04 (0.38) 0.98 (0.40)
L5 – average activity
count for five most
restful hours
Median (IQR) 1067 (621 to 2003) 981 (493 to 1940) 76.88 (−521.40 to
675.16)c
Start hour of five
most restful hours
(24h)d
Median (IQR) 01:00 (00:00 to
03:00)
01:00 (01:00 to
02:00)
M10 – average
activity count for
10 most active
hours
Median (IQR) 8247 (4258 to
12155)
8132 (5960 to
17158)
−198.29 (−1717.83
to 1321.25)c
Start hour of ten
most active hours
(24 h)
Median (IQR) 10:00 (8:00 to
11:00)
9:00 (8:00 to 10:00)
core night-time sleep measures N = 32 N = 17
Sleep efficiency (%)b Median (IQR) 79.0 (63.75 to 82.6) 80.9 (69.8 to 86.5)
Average sleep time
(min)
Median (IQR) 285 (243 to 303)
(N = 30)
291 (251 to 311)
(N = 17)
Average wake time
(min)
Median (IQR) 62 (43 to 80)
(N = 30)
49 (39 to 70)
(N = 17)
Notes: Sleep and core night-time measures are only for those with at least seven nights of data available. NPCRA (non-parametric circadian
rhythm analysis) data are those calculated with all 24-h periods with >3 h of missing data excluded.
IQR = interquartile range; SD = standard deviation.
aEstimates are from models adjusted for baseline score and site. Regression is OLS unless otherwise indicated.
bTime asleep\time in bed.
cQuantile (median) regression.
dTo calculate summaries, times have been ordered as night time i.e. from midday to midday the following day.
for the therapists on delivering sessions with
people with dementia present and managing any
resulting conflict and interpersonal challenges.
However, we recommend, only delivering the
intervention to people with dementia with a carer
also participating.
Strengths and limitations
We had envisaged that someone with sleep
disturbance and dementia would have a paid or
family member with them at night to ensure safety.
This was not always the case. When people lived
alone, the carers (whether family or paid) were
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unable to implement strategies, such as a scheduled
bedtime or wind down routine. It was also difficult
to gain reliable information about the sleep patterns
of people with dementia living alone. We would
therefore suggest excluding people without a night-
time carer in a full trial.
When paid carers attended the intervention they
were also able to implement strategies. Working
with them may be important to allow people to
remain living at home – care agencies require full-
day rates and two carers, if the carer is disturbed
frequently during the night. Since it appeared
feasible and is potentially useful, we would include
paid carers if people with dementia and their
families so wished in a full trial.
The trial recruited people from London only,
limiting external validity. Although male care
recipients were more likely to refuse, we succeeded
in recruiting carers from either gender, a range
of age groups, types and severity of dementia,
relationships to the care recipient, marital status,
and educational backgrounds. In particular, we
recruited about 35% of people of minority ethnic
status despite most studies finding they are under-
represented. A high proportion of carers remained
in the study. Although the outcome assessors were
masked to outcome, the participants were not. It
is possible that some carers might have felt that
they had to report a positive result to please the
researcher interviewing them, who was not the
therapist, but in most cases had met them for
screening and baseline assessment. However, the
instruments are validated, and in other studies
carers have frequently reported no beneficial effect
on these measures (Livingston et al., 2017). If the
person with dementia lived alone, the carer would
have been likely to report their relative’s memory
of their sleep and this assessment may be less
reliable.
This study finds that DREAMS-START is
a feasible and acceptable intervention. High
fidelity to the intervention suggests it can be
reliably delivered by trained, supervised psychology
graduates. The evidence from the validated
questionnaires suggests there is potential for
efficacy in improving sleep disturbance and quality
of life of the person with dementia, and for
reducing family carers’ stress. We are able to specify
primary and secondary outcomes for an efficacy
trial and calculate power. This augurs well for a full
trial.
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